Navigation Links
Dong-A PharmTech Co., Ltd. Announces Start of Phase III Trials for Udenafil, Its New Erectile Dysfunction Drug Under Development

SEOUL, Korea, Nov. 4 /PRNewswire/ -- Dong-A PharmTech Co. Ltd., announced that its U.S. partner, Warner Chilcott plc, has initiated two, phase III trials for udenafil, a new long acting drug under development for erectile dysfunction (ED). Each randomized, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of udenafil, an orally administered selective inhibitor of phosphodiesterase versus placebo. The trials will be conducted in 80 sites in the U.S. and will enroll approximately 1,120 subjects with ED.

Mr. Dong Hyun Park, President & CEO of Dong-A PharmTech, commented that, "We are extremely pleased to be entering the last phase of our udenafil development program in the United States with our partner Warner Chilcott. We are aiming to complete the remaining clinical trials for the udenafil erectile dysfunction program in the U.S. and European Union as well as most other major markets within 2 years. In addition, based on recent positive meetings with the USFDA, we anticipate initiating Phase 2b clinical trials which will evaluate the safety and efficacy of udenafil for benign prostatic hyperplasia (BPH) and pulmonary arterial hypertension (PAH)".

Udenafil was approved for marketing by the Korean Food and Drug Administration in November of 2005 and launched commercially in Korea in early 2006 under the trade name Zydena®. From 2006 to the first half of 2009, over 1,000,000 prescriptions for more than 6 million tablets of Zydena® were written for men with erectile dysfunction in Korea.

Zydena was also approved for marketing by the Russian Food and Drug Administration in July of 2008 and launched commercially in Russia in March 2009 under the trade name Zydena®.

If approved, udenafil is expected to participate in a growing prescription ED market by offering a long acting and safe product that will compete with Viagra® (Pfizer), Cialis (Lilly) and Levitra (Bayer/GSK).

About Dong-A PharmTech Co., Ltd.

Dong-A PharmTech is a late-stage pharmaceutical company incorporated in Korea, focused on the development and commercialization of udenafil worldwide excluding Korea.

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to FDA review and approval, product development and acceptance, manufacturing, competition, and/or other factors, which are outside the control of the Company.

                 Mr. Won Geun KIM
                 General Manager
                 Tel: +82 2 560 8008
                 Fax: + 82 2 563 6517

SOURCE Dong-A PharmTech Co. Ltd.

SOURCE Dong-A PharmTech Co. Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil
2. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), ... company,s second affiliate in Latin America . ... ... Colombia ... ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
(Date:6/23/2016)... The Biotechnology industry might still ... great opportunities to investors. assesses the recent performances ... XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... your complimentary trade alerts at: ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
(Date:6/24/2016)... ... 2016 , ... Today, MTI-GlobalStem, a provider of optimized transfection ... to transfect cells, announces its launch of the PluriQ™ G9™ Gene Editing System ... is a complete system for culturing and transfecting human pluripotent stem cells for ...
Breaking Medicine News(10 mins):